Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: J Mol Cell Cardiol. 2010 Oct 28;50(1):107–116. doi: 10.1016/j.yjmcc.2010.10.023

Fig. 4.

Fig. 4

Effect of TUDCA treatment on PA-induced cardiomyocyte contractile dysfunction. C57 (control) cardiomyocytes were incubated with PA (75 µM) at 37 °C for 2 hrs in the absence or presence of TUDCA (500 µM) prior to functional assessment. A: Resting cell length; B: Peak shortening (PS); C: Maximal velocity of shortening (+ dL/dt); D: Maximal velocity of relengthening (−dL/dt); E: Time-to-PS (TPS); and F: Time-to-90% relengthening (TR90). Mean ± SEM, n = 50–51 cells from 3 mice per group, * p < 0.05 vs. control, # p < 0.05 vs. PA group.